Cedar Mountain Advisors
CORT icon

Cedar Mountain Advisors’s Corcept Therapeutics CORT Stock Holding History

Cedar Mountain Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.84K Hold
16
– – ﹤0.01% 826
2026
Q2 		$1.39K Buy
+16
New +$966 ﹤0.01% 902
2026
Q1 		– Sell
-4
Closed -$139 – 1162
2025
Q4 		$139 Buy
+4
New +$314 ﹤0.01% 693

Other funds holding CORT

KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Stanley-Laman Group
Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Cedar Mountain Advisors's CORT Position: Q3 2026 in Review

Cedar Mountain Advisors held its Corcept Therapeutics (CORT) position steady in Q3 2026 at 16 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Cedar Mountain Advisors first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Cedar Mountain Advisors held 16 shares of Corcept Therapeutics worth $1.84K as of Q3 2026.
  • Cedar Mountain Advisors left its Corcept Therapeutics share count unchanged in Q3 2026.
  • Corcept Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #826 holding.
  • Cedar Mountain Advisors first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.